Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

Pharvaris (Nasdaq: PHVS) will present six abstracts, including three Featured Posters, at the AAAAI 2026 Annual Meeting in Philadelphia from February 27–March 2, 2026.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Pharvaris (Nasdaq: PHVS) will present six abstracts, including three Featured Posters, at the AAAAI 2026 Annual Meeting in Philadelphia from February 27–March 2, 2026. Key topics include pivotal Phase 3 RAPIDe-3 on-demand data, final CHAPTER-1 open-label results, and extended-release pharmacokinetics for CHAPTER-3.

Topline CHAPTER-3 results are anticipated in Q3 2026. Posters and slides will be posted on the company's investor site at the start of each presentation.

Argus Feb 10 session

+1.74% close to close Open Argus

Details

News Market Reaction – PHVS

In the Feb 10 session, PHVS gained 1.74%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Pharvaris’s plan to showcase pivotal RAPIDe-3 Phase 3 data and long-ter...

Analysis

This announcement highlights Pharvaris’s plan to showcase pivotal RAPIDe-3 Phase 3 data and long-term CHAPTER-1 results for deucrictibant at AAAAI 2026, including final efficacy and safety from roughly 3 years of treatment and extended-release pharmacokinetic findings. Historically, similar clinical-trial communications have produced mixed price reactions, with some strong moves and some declines. Key elements to watch include detailed efficacy, safety consistency, and how these data support the upcoming CHAPTER-3 and regulatory milestones.

Key Figures

Abstracts accepted: 6 abstracts Featured posters: 3 featured posters Meeting dates: February 27–March 2, 2026 +5 more

Abstracts accepted: 6 abstracts; AAAAI 2026 Annual Meeting presentations
Featured posters: 3 featured posters; AAAAI 2026 Featured Poster session
Meeting dates: February 27–March 2, 2026; AAAAI 2026 Annual Meeting in Philadelphia
Poster session time: 2:45–3:45 p.m. EST; Posters on February 27, 2026
Featured session time: 3:30–5:00 p.m. EST; Featured posters on March 1, 2026
Deucrictibant treatment duration: approximately 3 years; Final efficacy and safety results from CHAPTER-1 open-label portion
On-demand study phase: Phase 3; RAPIDe-3 pivotal trial for HAE attacks
Prophylaxis study phase: Phase 2 and Phase 3; CHAPTER-1 (Phase 2) and CHAPTER-3 (Phase 3) deucrictibant prophylaxis

Previous Clinical trial Reports

5 past events · Latest: Dec 03

Same Type 5 events

Dec 03
Pivotal topline data

24h Move

+21.8%

RAPIDe-3 Phase 3 met primary and all secondary endpoints with strong efficacy.
Jul 10
Timing update

24h Move

+7.2%

Updated RAPIDe-3 topline timing to Q4 2025 with NDA plans in 1H 2026.
Jun 27
Conference trial data

24h Move

-5.0%

Multiple deucrictibant trial results to be presented at HAEA Summit poster sessions.
Jun 02
Clinical data update

24h Move

-0.7%

Promising prophylactic and on-demand data plus validated biomarker assay at workshop.
Mar 03
Long-term data

24h Move

-3.6%

Long-term deucrictibant data for prevention and treatment at AAAAI/WAO congress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

bradykinin B2 receptor antagonists, hereditary angioedema, acquired angioedema due to C1 inhibitor deficiency, pharmacokinetic, +4 more

8 terms

bradykinin B2 receptor antagonists medical

"developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs"

Bradykinin B2 receptor antagonists are drugs that block a specific cell receptor which responds to bradykinin, a natural molecule that causes blood vessels to leak, swell and send pain signals; blocking that receptor can reduce swelling, pain and inflammation. For investors, these drugs matter because successful candidates can address acute or chronic conditions with high unmet need, and their clinical trial results, safety profile and regulatory approvals strongly influence a company’s market value—think of the drug as putting a cap on a leaking pipe to stop costly damage.

hereditary angioedema medical

"diseases such as hereditary angioedema (HAE) and acquired angioedema"

A rare inherited disorder that causes sudden, painful swelling under the skin or in internal tissues, including the airway, because a natural blood‑control protein is missing or not working. Attacks can be unpredictable and sometimes life‑threatening, so people often need ongoing medication or emergency treatment. For investors, hereditary angioedema represents a niche but stable market for specialized therapies, diagnostics, and emergency care solutions.

acquired angioedema due to C1 inhibitor deficiency medical

"acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH)"

A rare disorder where the body lacks or destroys a protein called C1 inhibitor, causing sudden, painful swelling in tissues such as the face, throat or abdomen; think of it as a faulty brake system that lets swelling responses run unchecked. For investors, it matters because its rarity and severity drive demand for specialized diagnostics, treatments and ongoing clinical development, affecting market opportunities, regulatory risk and potential healthcare spending.

pharmacokinetic medical

"and pharmacokinetic data of deucrictibant extended-release tablet"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

extended-release tablet medical

"deucrictibant extended-release tablet, which is being used in the pivotal Phase 3 study"

An extended-release tablet is a pill designed to release its active medicine slowly over many hours instead of all at once, like a faucet that drips steadily rather than a single pour. For investors, this matters because such formulations can improve patient convenience and adherence, change how often people buy or use a drug, affect safety and pricing, and often carry patent or market advantages that influence a product’s commercial value.

open-label medical

"final data from the open-label portion of CHAPTER-1, the Phase 2 study"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

kinin biomarker assay medical

"results from our novel kinin biomarker assay."

A kinin biomarker assay is a laboratory test that measures levels or activity of kinin peptides and related proteins, molecules that signal inflammation and changes in blood vessel behavior. Investors should care because these tests help developers show whether a drug or diagnostic affects key disease pathways, guide clinical trial decisions, and influence regulatory and commercial prospects — like a smoke detector revealing whether an anti-inflammatory treatment is actually reducing biochemical “smoke.”

Phase 3 medical

"pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

02/10/2026 - 06:50 AM

Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time

ZUG, Switzerland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced the acceptance of six abstracts for poster presentation, three of which will be presented during the Featured Poster session, at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, to be held from February 27-March 2, 2026, in Philadelphia, PA.

“Following the announcement of topline RAPIDe-3 data in December of last year, the AAAAI Annual Meeting provides Pharvaris with the first opportunity to share the positive study results with the broader medical community at a large scientific congress,” said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris. “We will also be presenting final data from the open-label portion of CHAPTER-1, the Phase 2 study of deucrictibant for prophylaxis of HAE attacks, and pharmacokinetic data of deucrictibant extended-release tablet, which is being used in the pivotal Phase 3 study of deucrictibant for long-term prophylaxis of HAE attacks, CHAPTER-3. Final efficacy and safety results from approximately three years of deucrictibant treatment from CHAPTER-1 and the data providing further evidence of an optimized extended-release formulation provide strong foundations in advance of the results of CHAPTER-3, topline data from which is anticipated in the third quarter of this year. Additionally, we will be presenting on-demand endpoint validation findings, as well as results from our novel kinin biomarker assay.”

Details of the presentations are as follows:

Title: A Novel Kinin Biomarker Assay for Characterization of Different Types of Bradykinin-Mediated Angioedema
Presenter: Evangelia Pardali, Ph.D.
Poster Number: 078
Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST
Title: Content Validity of the Angioedema syMptom Rating scAle (AMRA) to Assess Symptoms of Hereditary Angioedema Attacks
Presenter: Teresa Caballero, M.D., Ph.D.
Poster Number: 154
Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST
Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
Presenter: Michael E. Manning, M.D.
Poster Number: 159
Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST
Title: Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Study
Presenter: Marc A. Riedl, M.D., M.S.
Featured Poster Number: 831
Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST
Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
Presenter: John Anderson, M.D.
Featured Poster Number: 832
Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST
Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
Presenter: Zhi-Yi Zhang, Ph.D.
Featured Poster Number: 834
Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST

The abstracts are available to view in an online supplement to The Journal of Allergy and Clinical Immunology (JACI) at jacionline.org.

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing global marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/.

Contact
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What RAPIDe-3 data will Pharvaris (PHVS) present at AAAAI 2026?

Pharvaris will present pivotal Phase 3 RAPIDe-3 on-demand results for deucrictibant from RAPIDe-3. According to the company, these are the first full presentations of topline Phase 3 data to the medical community at a major congress.

When will Pharvaris (PHVS) present CHAPTER-1 long-term results at AAAAI 2026?

Pharvaris will present final CHAPTER-1 open-label extension results during the AAAAI meeting on February 27 and March 1, 2026. According to the company, the data include approximately three years of deucrictibant treatment for prophylaxis.

What CHAPTER-3 timeline did Pharvaris (PHVS) provide at AAAAI 2026?

Pharvaris anticipates topline CHAPTER-3 results in the third quarter of 2026. According to the company, CHAPTER-3 uses an optimized extended-release tablet evaluated in presented pharmacokinetic data.

How can investors access Pharvaris (PHVS) posters and slides from AAAAI 2026?

Investors can view posters and presentation slides on the company's investor website when each presentation begins. According to the company, materials will be posted at ir.pharvaris.com/news-events/events-presentations.

Which specific deucrictibant topics will Pharvaris (PHVS) cover at AAAAI 2026?

Presentations cover a kinin biomarker assay, AMRA symptom-scale validation, RAPIDe-3 on-demand results, CHAPTER-1 long-term efficacy/safety, and extended-release PK. According to the company, six abstracts were accepted, three as Featured Posters.

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

Rhea-AI Summary

Positive